Investigation reveals tumor progression linked to BRAF V600E mutation in papillary thyroid carcinoma, suggesting implications for diagnosis.
The presence of infiltrative tumor margin, plump pink cells, and myxoid desmoplasia, may serve as active markers associated with the normalized BRAF V600E mutation. These findings suggest that the mutation acts as a driver in both early and late stages of PTC development. Furthermore, a direct relationship between tumor size and clonality underscores the role of BRAF V600E mutation in tumor progression and morphological evolution.
No takes yet. Share an insight, caveat, or question.
Martínez-Martín et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: